Prognostic value of immunohistochemical expression profile of epidermal growth factor receptor in urothelial bladder cancer

J Immunoassay Immunochem. 2016;37(4):359-67. doi: 10.1080/15321819.2016.1146757.

Abstract

We studied epidermal growth factor receptor (EGFR) expression profile in urothelial bladder carcinoma (UBC) which is a complex and heterogeneous disease with a large spectrum of histological aspects and deadly potential. Using immunohistochemistry (IHC), all GI tumors and pTa cases showed a low expression profile of EGFR. However, we note that when the stage of disease is advanced, tumors over-express EGFR. Indeed, 5% and 25% of GII and GIII tumors over-expressed EGFR, respectively. Further, 0% of pTa, 9,5% of pT1, 15% of pT2, 50% of pT3, and 90% of pT4 tumors were shown to be high EGFR expression (HEE). Moreover, we found a statistically significant correlation between the EGFR over-expression and grade and stage (P < 0.05). Thus, EGFR over-expression could be a potential prognostic marker to predict poor outcome in Tunisian patients with UBC.

Keywords: EGFR; immunohistochemistry; marker; over-expression; prognosis; urothelial bladder cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biomarkers, Tumor / analysis*
  • Biomarkers, Tumor / biosynthesis
  • Biomarkers, Tumor / immunology
  • ErbB Receptors / analysis*
  • ErbB Receptors / biosynthesis
  • ErbB Receptors / immunology
  • Humans
  • Immunohistochemistry
  • Prognosis
  • Urinary Bladder Neoplasms / diagnosis*
  • Urinary Bladder Neoplasms / immunology
  • Urinary Bladder Neoplasms / metabolism*

Substances

  • Biomarkers, Tumor
  • ErbB Receptors